Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Trillium Therapeutics -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (124)	12/18/2017 2:29:54 PM
From: semi_infinite	Read Replies (1) \| Respond to of 294

I am trying to understand your expectations better. What are they in terms of valuation based upon current results? I have a small amount bought in the 6s and added/traded some to lower my cost basis on the big move from the 5s. The results are intriguing but still inconclusive so I expect volatility to continue. Potential indication for SS should set some floor on valuation and I am tempted to add at these levels and below.

To: scaram(o)uche who wrote (124)	12/18/2017 7:12:30 PM
From: Ian@SI	Read Replies (1) \| Respond to of 294

Could just be Y/E selling by a fund. TRIL is relatively illiquid. Fund may prefer not to show a losing biotech in its YE reports. If this is the driver, we could expect to see a bounce in January. i.e. this is your item C but without management collusion.